Skip to main content

Priapism

Priapism is a persistent penile erection lasting more than 4 hours that continues beyond, or is unrelated to, sexual stimulation.[1][2] It is classified by pathophysiology into three subtypes: ischemic (low-flow, veno-occlusive), non-ischemic (high-flow, arterial), and stuttering (recurrent ischemic), each with different management pathways. Ischemic priapism accounts for roughly 95% of cases and is a urologic emergency: beyond 4 hours, progressive ischemia, acidosis, smooth-muscle injury, and fibrosis destroy corporal tissue, and longer duration reduces the chance of erectile recovery.[24] Medical detumescence can still succeed after 24–36 hours.[3][4]

The combined 2022 AUA/SMSNA guideline includes acute ischemic, recurrent ischemic, sickle-cell-associated and non-ischemic priapism, and prolonged erections after intracavernosal medication. Its acute ischemic recommendations were first published in 2021.[2][3][25]

Classification and Pathophysiology​

Ischemic (low-flow, veno-occlusive) priapism​

Venous outflow obstruction causes blood stasis in the corpora cavernosa, followed by progressive hypoxia, hypercapnia, acidosis, and eventually smooth-muscle necrosis and fibrosis. The corpora are rigid and painful; the glans is soft (spongiosum is not involved).[1]

Corporal blood gas:

ParameterIschemicNormal arterial
pO₂<30 mmHg>90 mmHg
pCO₂>60 mmHg<40 mmHg
pH<7.25~7.40
ColorDark, deoxygenatedBright red

These are the typical values in AUA/SMSNA Table 5; non-ischemic corporal blood resembles arterial blood.[25]

Non-ischemic (high-flow, arterial) priapism​

Uncontrolled arterial inflow via an arteriocavernosal fistula, usually after blunt perineal or penile trauma (straddle injury, saddle trauma). The corpora remain oxygenated; the erection is partial and non-painful. AUA/SMSNA recommends an initial period of observation for diagnosed non-ischemic priapism .[1][4][25]

Stuttering (recurrent ischemic) priapism​

Recurrent confirmed ischemic episodes with intervening detumescence; episodes may last less than or more than four hours.[3][5][25]

Molecular mechanisms (ischemic)​

  • Dysregulation of the NO–cGMP–PDE5 pathway; chronic hypoxia reduces endothelial NO and alters PDE5 set-point
  • Rho-Rho kinase pathway dysregulation
  • Adenosine accumulation signals through the A2B receptor to drive fibrosis[6]
  • Oxidative stress and reactive-oxygen-species injury
  • In sickle-cell disease, intravascular hemolysis leads to impaired NO bioavailability, exaggerated corpus cavernosum relaxation and sickling in the corpora during nocturnal tumescence[7][8]

Epidemiology and Etiology​

CauseComment
Sickle cell diseaseImportant cause, especially in children; lifetime prevalence estimates vary and may approach half of men with SCD.[5][9]
Intracavernosal injection therapyMajor cause: papaverine, phentolamine, PGE1 (alprostadil). Can account for >50% of cases in some series[10]
MedicationsAntidepressants (e.g., trazodone) and antipsychotics (e.g., chlorpromazine, risperidone), α-blockers, anticoagulants, recreational cocaine
Hematologic disordersThalassemia, polycythemia vera, multiple myeloma, CML/CLL
MalignancyMetastatic infiltration of corpora (rare but reported; bladder, prostate and renal primaries)
NeurologicSpinal cord injury (especially cervical), autonomic dysreflexia
IdiopathicSignificant proportion of adult cases
TraumaPerineal or straddle injury; causes non-ischemic (high-flow) priapism specifically. Other reported non-ischemic causes include cavernosal artery laceration from intracavernosal injection therapy, iatrogenic injury from a prior surgical shunt for ischemic priapism, penile revascularization surgery, Peyronie's surgery, and penile tattooing; priapism after spinal cord injury is also more often non-ischemic than ischemic[28][29][30][31][32]

In one 2006–2009 US emergency-department analysis limited to visits with a primary priapism diagnosis, the visit rate was 5.34 per 100,000 males per year, with a 31.4% higher rate in summer than winter; 13.3% of those visits led to admission. A separate analysis of ED encounters with a priapism code estimated mean total annual charges of about $123.9 million, 86.8% from inpatient admissions.[33][34]

Initial Evaluation​

History​

AUA/SMSNA calls for medical, sexual and surgical history and examination of the genitalia and perineum .[25]

  • Baseline erectile function
  • Duration of erection (drives the urgency of intervention)
  • Preceding sexual activity, perineal trauma, recreational drugs, new medications
  • Prior priapism episodes (stuttering pattern)
  • Known sickle-cell, thalassemia, leukemia
  • Current ICI use and agent
  • Prior urological surgery, specifically an indwelling penile prosthesis. An inflated or malfunctioning prosthesis can be mistaken for priapism on history and exam; confirming implant status before corporal aspiration or phenylephrine avoids a wasted or harmful procedure on a prosthetic cylinder

Physical examination​

  • Ischemic: rigid corpora, soft glans, painful
  • Non-ischemic: partially tumescent, non-painful, may have perineal ecchymosis
  • Examine perineum and genitalia for evidence of recent trauma

Laboratory testing​

EAU 2026 recommends a full blood count with white-cell differential and platelets plus a coagulation profile ; it also recommends haemoglobinopathy screening for patients with low-flow priapism at high risk of sickle cell disease or thalassaemia .[24] Perform testing alongside urgent corporal treatment.[24][25]

Corporal blood gas​

Corporal blood gas is the reference test for distinguishing subtypes. A 19–21 gauge needle is placed laterally into the corpus cavernosum (avoiding the dorsal neurovascular bundle at 12 o'clock and the urethra at 6 o'clock). Aspirate; color is the first clue. Send for gas analysis. AUA/SMSNA recommends corporal blood gas at initial presentation .[25] Its discussion permits omission at clinician discretion when the diagnosis is clear, including ICI-induced or known recurrent ischemic episodes. Aspiration is also therapeutic; etiologic testing must not delay definitive treatment .[1][4][25] Reported needle/catheter gauges for this same lateral corporal access vary across sources (16–21 gauge); when higher-volume therapeutic aspiration and irrigation are anticipated, a larger-bore angiocatheter (16–18 gauge) drains viscous, deoxygenated blood more efficiently than a narrow-gauge needle.[27] AUA Appendix B uses a 16–18-gauge butterfly needle near the base at 3 or 9 o'clock in its sample aspiration protocol.[25] In an anesthetized patient, a large-bore needle (14–16 gauge) can instead be placed transglanularly, through the tip of the glans into both corpora; the needle is left in situ rather than repeatedly placed and withdrawn, and connecting tubing between the two corpora can allow aspirating old blood from the contralateral side through a single access point.[36] A transglanular rather than lateral-shaft needle entry has also been reported to reduce the chance of significant shaft ecchymosis and hematoma formation, without a comparative outcome study.[42]

Imaging​

  • Color Doppler ultrasound (CDUS) may be used when the ischemic versus non-ischemic diagnosis is indeterminate .[25] EAU 2026 recommends penile and perineal duplex before corporal aspiration , because aspiration can produce aberrant flow that mimics a non-ischemic or reperfusion picture, and recommends blood gas analysis of aspirated corporal blood in the emergency setting to distinguish the subtype .[24] Ischemic: absent or minimal cavernosal arterial flow. Non-ischemic: high arterial flow, often with visible arteriocavernosal fistula.[11][12] In a 52-patient cohort, all non-ischemic cases had a peak systolic velocity above 50 cm/sec, while pre-shunt ischemic cases had peak systolic velocity below 50 cm/sec (some with a high-velocity, high-resistance pattern and diastolic reversal after aspiration); post-shunt ischemic cases had overlapping, variable findings that did not predict outcome.[35]
  • MRI may help assess cavernosal viability in prolonged or refractory cases. AUA/SMSNA states that MRI is unlikely to have a role in the initial diagnostic and treatment phase because of the urgency of ischemic priapism.[25] EAU 2026 gives MRI a weak recommendation for prolonged or refractory ischemic priapism as an adjunct to predict smooth-muscle viability.[24] In one 38-patient study, only 23 had paired MRI and corporal biopsy; sensitivity for nonviable smooth muscle was 100% in that paired subset.[43]
  • CT/MR angiography defines pudendal arterial anatomy for selective embolization in non-ischemic priapism. AUA/SMSNA instead advises considering penile duplex assessment of fistula location and size , with scanning of the shaft and perineum before embolization; it does not call for routine CT or MR angiography.[25]

Management — Ischemic Priapism (the Acute Emergency)​

AUA/SMSNA recommends prompt first-line treatment with intracavernosal phenylephrine and corporal aspiration, with or without irrigation .[25] Observation, oral medication, cold compresses and exercise should not delay definitive therapy for diagnosed acute ischemic priapism .[25] The pathway allows earlier surgical escalation according to ischemia duration, response and patient goals.[2][25]

First-line treatment — aspiration plus phenylephrine​

Through a lateral corporal needle, aspirate dark blood and clots, irrigating with saline as needed until fresh red blood returns; then assess detumescence.[24][25] Combine aspiration with intracavernosal phenylephrine, with or without saline irrigation, for acute ischemic priapism.[25] For a prolonged erection lasting four hours or less after intracavernosal ED medication that warrants intervention, AUA/SMSNA recommends intracavernosal phenylephrine as the initial treatment ; patients receiving intracavernosal teaching or an in-office pharmacologically induced erection should be instructed to return to the office or Emergency Department for an erection lasting >4 hours .[25] After treatment, edema, ecchymosis or partial tumescence may mimic ongoing ischemia. Persistent erection after shunting requires corporal blood gas or Doppler assessment before further surgery .[25]

Intracavernosal phenylephrine within first-line treatment​

Phenylephrine is the α-agonist of choice because of α1 selectivity and avoidance of β-mediated cardiac stimulation; hypertension and other serious cardiovascular effects remain possible.[13]

  • Use a verified dilute preparation, ideally pharmacy-prepared, with independent concentration/dose checks and BP/heart-rate monitoring.
  • AUA Appendix A. Give 100–500 micrograms in 1 mL normal saline, optimally premixed by pharmacy, with doses at least five minutes apart. Aspirate before injection when combining treatments. Monitor blood pressure and heart rate and stop injections for blood-pressure changes. Appendix B separately describes a sample aspiration/irrigation cycle with a 3–5-minute wait after injection and a firm-wrap option for rapid refilling.[25]
  • EAU adult regimen: 200 micrograms intracavernosally every 3–5 minutes, maximum 1 mg within one hour . At 200 micrograms/mL, each dose is 1 mL. Different institutional/AUA-based regimens exist; avoid mixing a concentration from one protocol with a volume from another.[24]
  • Children and significant cardiovascular disease: reduce dose and individualize under specialist supervision; a universal pediatric 100-microgram dose/500-microgram ceiling is not established by these guidelines.[24]
  • EAU advises avoiding sympathomimetics in malignant/poorly controlled hypertension and with MAO inhibitors; its algorithm footnote also lists a history of cerebrovascular disease as a contraindication and advises pulse and blood-pressure checks during injection and every 15 minutes for one hour afterward.[24] Monitor during administration and for adverse effects afterward; stop/escalate for cardiovascular intolerance.[24] AUA/SMSNA instead discusses cautious intracavernosal use with MAO inhibitors, using low starting doses, gradual escalation and cardiovascular monitoring (Appendix A); this differs from the EAU contraindication.[25]

Repeat aspiration and irrigation within first-line treatment​

Corporal saline irrigation and re-aspiration may accompany phenylephrine to clear stagnant blood and coagulum. These are components of combined first-line treatment. AUA advises definitive treatment when repeated attempts over about one hour fail, with earlier escalation appropriate for prolonged ischemia or poor response. Do not restart an additional hour of irrigation after an unsuccessful injection protocol.[25]

Surgical shunting — for persistent ischemia despite first-line treatment​

The shunt creates a communication between the rigid corpus cavernosum and either the glans or the corpus spongiosum, allowing stasis blood to drain.

For detailed operative technique comparisons, see Priapism Shunts & Decompression.

Distal shunts (usual first surgical approach):

ShuntTechnique
WinterPercutaneous large-bore biopsy needle (Tru-Cut) through the glans into the distal corpus cavernosum, creating a fistula
EbbehojStab incision with a scalpel through the glans into the distal corpus cavernosum
T-shuntT-shaped scalpel incision distally through the glans into corpus cavernosum (variant of Ebbehoj)
Al-GhorabOpen excision of distal tunica albuginea through a glanular incision; no shunt has established universal comparative superiority

Historical proximal/venous shunts: counsel that evidence is inadequate to quantify their benefit after distal failure .[25]

Tunneling and alternative decompression​

Tunneling extends the distal shunt by passing a dilator (Hegar or Mecholl) proximally through the cavernosum from the shunt site to disrupt ischemic coagulum along the entire length of the corpus. AUA/SMSNA recommends a distal shunt with or without tunneling after first-line treatment fails (statement 10) and considering tunneling for persistent ischemia after a distal shunt (statement 11; both Moderate Recommendations, Grade C).[25] Comparative evidence is limited.[2][25]

  • Burnett snake technique. Al-Ghorab shunt with retrograde corporal tunneling with a 7/8 Hegar dilator in prolonged ischemic priapism (more than 48 hours).[24]
  • Penoscrotal decompression (PSD). Glans-sparing proximal corporal decompression through penoscrotal or proximal shaft corporotomies; increasingly used as salvage after failed distal shunts and as an alternative primary surgical strategy for prolonged ischemic priapism[14][18][19][20]

Step 5b — Penoscrotal decompression (PSD)​

PSD treats prolonged ischemic priapism as a corporal compartment syndrome. Instead of creating a corporoglanular fistula through the glans, PSD opens the proximal corpora, evacuates stagnant blood and clot directly, irrigates the corporal bodies, and closes the corporotomies. This can spare the glans and avoid some distal-shunt complications while preserving the option for later elective penile prosthesis placement if erectile function does not recover.[18][19]

When to consider PSD:

ScenarioRole of PSD
Failed aspiration / irrigation / phenylephrineSurgical decompression option when medical detumescence fails
Failed distal shunt or failed corporoglanular tunnelingSalvage strategy that bypasses the glans and directly clears proximal corporal clot
Prolonged ischemic priapism, especially >36–48 hAlternative to glans-based shunting in centers familiar with the technique; counsel that erectile recovery remains time-dependent
PSD failure or very late presentation with nonviable corporaConfirm persistent ischemia and discuss prosthesis timing or symptom-focused management through shared decision-making

Technique options:

ApproachExposureTechnical notes
Original penoscrotal approachLongitudinal or transverse incision at the penoscrotal junction; familiar to implant surgeonsExpose ventrolateral tunica, protect urethra with a Foley catheter, make a 2-cm longitudinal corporotomy in each corpus selected for decompression, evacuate dark blood and clot, irrigate to clear return, and close the tunica with absorbable suture; the cited series used unilateral and primary bilateral decompression[18][19]
Modified proximal shaft approachProximal penile shaft incision or degloving exposure, analogous to penile fracture repairMay make bilateral corporal exposure faster and more familiar for general urologists comfortable with fracture exploration; evacuation, irrigation, and tunical closure are otherwise the same[20]

Operative pearls:

  • Place a Foley catheter before dissection so the urethra / corpus spongiosum can be palpated and protected.
  • Put corporotomies on the ventrolateral corporal surface, away from the dorsal neurovascular bundle and away from the urethra.
  • Evacuate aggressively but deliberately: prolonged cases often contain viscous, gelatinous, or organized clot that will not drain through a small distal shunt.
  • Laterality evidence is observational. In a 25-patient series, recurrence occurred after 2/10 unilateral versus 0/15 primary bilateral procedures.[19] In a later 26-patient series, 22 underwent bilateral decompression, with pain resolution and no recurrence in 73%; only four underwent unilateral decompression.[19][20]
  • Apply a light compressive dressing after closure; monitor for recurrent rigidity, hematoma, skin issues, and early pain relief.

Step 6 — Early penile prosthesis implantation​

AUA/SMSNA permits consideration of a prosthesis for untreated acute ischemic priapism >36 hours or refractory disease after shunting, with or without tunneling .[25] It recommends counseling that erectile recovery is unlikely after >36 hours and discussing early versus delayed placement .[25] Its discussion defines early placement as within two weeks. EAU recommends discussing implantation after delayed presentation (>48 hours) or failed injection/distal-shunt therapy .[2][3][24][25]

  • After more than 36 hours of confirmed untreated ischemic priapism, erectile recovery is unlikely.[25] Verify the duration, including any intervening detumescence.
  • Early implantation can avoid later dense fibrosis and length loss, but carries infection/erosion risks. EAU advises delaying implantation after a shunt to reduce those risks , and notes that interventions beyond 48–72 hours can relieve the erection and pain but do little to prevent later ED.[24]
  • Discuss early versus delayed placement, device choice and the patient's goals. A malleable device can later be exchanged for an inflatable implant; neither implantation nor one device type is mandatory.[15][24]

See penile implants — revision scenarios for the cavernotome toolkit and other techniques used in the fibrosed corpus.

Special Considerations — Sickle Cell Disease​

AUA/SMSNA advises against delaying standard acute treatment for disease-specific systemic interventions .[3][25]

  • Exchange transfusion. AUA/SMSNA advises against its use as primary treatment and that no data show it ends episodes sooner than standard procedures or the natural history. Waiting to arrange it delays effective intervention while ischemic injury progresses; the guideline notes that preparation and exchange with extended-antigen-matched red cells usually takes six hours or more.[25]
  • Perioperative transfusion in SCD. When haemoglobin is near the patient's usual value, transfusion is not indicated. If shunting requires general anaesthesia, discuss possible simple transfusion toward Hb 9–10 g/dL with hematology; avoid overtransfusion and do not delay urgent corporal treatment.[25]
  • ASPEN syndrome (association of sickle cell, priapism, exchange, and neurologic events) has been described after rapid exchange transfusion; this is another argument against reflexive exchange.
  • Sequencing. Treat acute SCD-associated ischemic priapism with phenylephrine and corporal aspiration, with or without irrigation, before escalating to shunting. Cold compresses and cold irrigation are avoided because they can precipitate intravascular sickling.[2][3][25]

Chronic prevention in SCD​

After an acute episode resolves, prevention of recurrence is the main goal:

  • Hydroxyurea. Established SCD therapy; its specific benefit for recurrent priapism remains uncertain. In the PIN trial, semen analysis in 40 men with sickle-cell anemia showed lower sperm concentration, motility and normal morphology on hydroxyurea, with group measures returning to pretreatment levels three months after stopping it.[26]
  • Scheduled monthly transfusion programs in selected patients
  • Pseudoephedrine at bedtime (limited evidence)
  • PDE5 inhibitors. Low-dose daily sildenafil has been used with the paradoxical rationale of restoring PDE5 regulatory tone; evidence is limited but mechanism is biologically plausible[5]
  • GnRH analogues / antiandrogens. Specialist options with limited evidence; counsel about libido, erectile function, fertility and effects on sexual maturation

Management — Non-Ischemic (High-Flow) Priapism​

Non-ischemic priapism is not a medical emergency.[1][3] In a six-patient high-flow series, all reported ED or distal penile flaccidity at a median 4.5-week follow-up; assess erectile function and discuss embolization timing during observation.[24]

Management pathway:

  1. Observation and conservative measures. Observation and site-specific compression; cold measures are avoided in patients with sickle cell disease.[24][25]
  2. Some non-ischemic fistulas close spontaneously during observation; the chance of resolution for an individual patient is uncertain.[24] The AUA/SMSNA guideline advises counseling that non-ischemic priapism is not an emergency and offering an initial period of observation .[25] EAU 2026 likewise treats it as non-emergent, with definitive management at the treating physician's discretion , site-specific perineal compression as the first step , and androgen deprivation considered only in adults [24]
  3. Selective arterial embolization. AUA/SMSNA recommends offering embolization when non-ischemic priapism persists after observation and the patient wishes to be treated .[25]
    • Temporary agents include autologous clot and absorbable gelatin sponge (Gelfoam); material choice depends on anatomy, prior treatment and interventional expertise
    • Permanent agents include coils and some particles/glues. AUA/SMSNA found no direct comparison establishing an optimal material or a firm difference in erectile outcomes between resorbable and non-resorbable agents; EAU prefers temporary material for a first embolization .[24][25] In a 15-patient series, 11/15 (73%) had no recurrence on postoperative Doppler, 3/15 (20%) needed repeat embolization, and 3/15 (20%) reported a slight change in erection quality at an average 55-month follow-up.[38] In a separate 27-patient series, 24/27 (89%) achieved complete resolution after one embolization, while 2/27 (7%) needed repeat embolization; 18/23 (78%) with normal baseline erectile function maintained potency during a mean 13-month follow-up.[37] Rare complications include perineal abscess, gluteal ischemia and penile gangrene. Counsel about recurrence and ED; comparative estimates are limited by selection and technique.[37][38][39][40][41] Separately, AUA/SMSNA's heterogeneous 42-study summary reported successful correction in 85% and priapism recurrence over time in 15%; erectile-function outcomes were inconsistently reported.[25]
  4. Surgical ligation. AUA/SMSNA recommends repeat embolization over surgical ligation for persistent erection after fistula embolization , and counseling that embolization carries risks of ED, recurrence and failure to correct non-ischemic priapism .[25] EAU 2026 recommends embolization when conservative management fails , a first embolization with temporary material , repeat embolization with temporary or permanent material for recurrence , and fistula ligation only as a final option after repeated embolization fails , given a high risk of ED with ligation.[24]

Follow-up. Examine the penis, assess erectile function, and obtain unstimulated color Doppler ultrasound one to two weeks after resolution to confirm fistula closure.[11][24]

Management — Stuttering / Recurrent Ischemic Priapism​

Stuttering (recurrent) ischemic priapism should be distinguished from sleep-related painful erections, a separate entity causing frequent nighttime awakenings from penile pain due to prolonged but non-ischemic nocturnal erections. Management of true stuttering priapism is further complicated by the broad spectrum of presentations in number, frequency and length of the prolonged erections.

Acute episode: when a recurrent erection persists >4 hours and ischemic priapism is confirmed, use the acute pathway with corporal aspiration and intracavernosal phenylephrine; selected earlier episodes may follow a trained, clinician-directed abortive plan.[3][24][25]

Preventive strategies. The 2022 AUA/SMSNA guideline advises informing patients that optimal prevention strategies are unknown and that hormonal regulators may impair fertility and sexual function .[25] It describes at-home phenylephrine as reasonable for aborting episodes but not as a preventive strategy.[25] EAU 2026 rates its stuttering-priapism recommendations weak (level 3), apart from treating each acute episode as ischemic priapism ; its list adds hormonal therapy for frequent relapses (not before sexual maturity), PDE5 inhibitors started only when flaccid, and digoxin, alpha-adrenergic agonists, baclofen, gabapentin or terbutaline only for frequent, uncontrolled relapses.[24] Options reported in the literature:[3]

  • At-home phenylephrine self-injection. For episodes not yet meeting 4-hour threshold; patient must be thoroughly trained and aware of hypertensive-crisis risk
  • Daily low-dose PDE5 inhibitor. An off-label preventive option with limited evidence; begin only while flaccid, not to treat an acute episode
  • α-agonist agents (pseudoephedrine, etilefrine where available)
  • Ketoconazole. Off-label specialist option; requires attention to hepatotoxicity, adrenal suppression and drug interactions
  • GnRH analogues / antiandrogens. Limited-evidence options with fertility and sexual-function consequences; avoid before sexual maturation
  • Hydroxyurea / chronic transfusion for SCD-associated stuttering

PIN trial (2025): In 64 men with sickle-cell anemia, this phase 2 feasibility trial did not establish added preventive benefit from tadalafil over placebo when both groups received hydroxyurea (between-group p = 0.654; median follow-up 10 months). Discuss prevention individually with hematology and sexual-medicine specialists.[26]

Outcomes​

Duration is the dominant predictor of ED​

DurationRisk of ED
<12 hoursIn a single-center retrospective analysis of ischemic priapism, adjusted ORs for de novo ED versus 0–4 hours (n = 25) were 1.91 at 4–8 hours (n = 53; 95% CI 0.34–15.4) and 1.90 at 8–12 hours (n = 21; 95% CI 0.20–18.6).[10]
12–20 hoursIn a single-center retrospective analysis of ischemic priapism, the adjusted OR for de novo ED was 2.87 versus 0–4 hours (n = 18; 95% CI 0.40–25.8).[10]
20–36 hoursIn a single-center retrospective ischemic-priapism analysis, the adjusted OR for de novo ED was 25.2 versus 0–4 hours (n = 12; 95% CI 2.79–355).[10]
36 hours or longerIn a single-center retrospective ischemic-priapism analysis, the adjusted OR for de novo ED was 61.3 versus 0–4 hours (n = 47; 95% CI 11.8–530).[10]
>48 hoursRecovery is less likely.[16]

Other predictors​

  • In the 35-patient follow-up cohort, complete detumescence was the only significant predictor in multivariable analysis.[16]
  • MRI in a small follow-up series. Five patients with penile fibrosis had heterogeneous low-signal areas attributed to hemosiderin and fibrosis.[16]
  • In a single-county-hospital study of 334 ischemic-priapism encounters, phenylephrine and/or aspiration resolved 78%; some episodes >36 hours still responded[17]
  • In that same cohort, shunting occurred in 10%, with lower rates for SCD (2.2%) than other etiologies (15.2%)[17]

Long-term complications​

  • Erectile dysfunction. The dominant long-term morbidity
  • Penile fibrosis. Adenosine-A2B signaling contributed to fibrosis in mouse models; fibrosis was detected in 20/35 (57%) patients in a followed mixed-duration cohort, more often after episodes >48 hours[6][16]
  • Penile shortening. Especially with delayed prosthesis implantation
  • Acquired penile curvature
  • Psychological distress and relationship-impacting sexual dysfunction[5]

Prolonged Ischemic Priapism — Escalation and Prosthesis Decisions​

Prolonged ischemia increases the likelihood of failed medical treatment and later ED. Treat promptly and escalate according to response, confirmed perfusion and the patient's goals.[2][17][24]

Distal shunts alone have limited durability in prolonged cases because the ischemic coagulum spans the entire corporal length. Success of traditional distal shunting falls as duration passes 36–48 hours, and glans-based shunts can be limited by recurrent occlusion, urethral injury, cavernosospongiosal fistula, and the inability to clear proximal clot.[14][18][23]

Where PSD fits​

PSD is a glans-sparing proximal decompression option after failed medical treatment, including selected cases before or after distal shunting. Its place depends on presentation and expertise.[24]

Evidence anchorFindings
Fuchs 2018In a retrospective series of 14 patients with refractory ischemic priapism after failed distal shunting, all six later PSD cases detumesced with immediate pain relief; three of eight earlier malleable-implant cases required eight revisions, including for extrusion, over a median 41.5-month follow-up.[18]
Baumgarten 202025 patients/27 PSD procedures; recurrence 2/10 unilateral versus 0/15 primary bilateral. Spontaneous penetrative erections were reported by 9/15 with documented sexual follow-up.[19]
Basile 2025Two-center retrospective series, 26 patients: immediate detumescence 96%, pain relief 92%, composite success 18/26 (69%), complications 2/26. Thirteen of 26 later received a penile prosthesis, with infection requiring explantation in 2/13[20]
VanDyke 2023/2024 surgeon surveyAmong high-volume male-genital surgeons who had performed both procedures, PSD was perceived as more effective than corporoglanular tunneling (47.3% vs 18.7% rating "very or extremely effective"), although tunneling remains more widely performed[21]

Practical approach:

  1. Prompt aspiration/irrigation plus phenylephrine, with cardiovascular monitoring.
  2. If ischemia persists, distal shunting ± tunneling; EAU also permits PSD as an alternative first surgical option with a weak recommendation.[24]
  3. After a shunt, persistent tumescence may reflect reperfusion rather than ongoing ischemia: reassess with corporal blood gas before repeat surgery; Doppler may be misleading during post-decompression hyperemia.[2][24] Ischemic priapism can evolve into a non-ischemic, high-flow state after treatment, especially after a cavernoglanular or proximal shunt: the shunt itself can create the arteriovenous communication that produces a high-flow picture on repeat exam, which is why equivocal post-shunt tumescence is worked up with color Doppler or blood gas rather than assumed to be treatment failure.
  4. Discuss prosthesis options for prolonged confirmed ischemia or refractory disease, including the effect of recent shunting on timing and complication risk.

PSD vs acute prosthesis​

PSD avoids implanting hardware into swollen, ischemically injured tissue and keeps later inflatable penile prosthesis placement available under more controlled conditions. That is its major appeal. Its limitation is equally important: decompression may relieve pain and rigidity without restoring erectile function if smooth-muscle necrosis has already occurred.

Early penile prosthesis remains appropriate when the presentation is very late, corporal viability is doubtful, the patient prioritizes length preservation over native erectile recovery, or PSD / shunting fails. The EAU systematic review found prosthesis reliably resolves priapism but carries nontrivial complication risk, while post-shunting reviews emphasize that evidence after failed shunting remains retrospective and center-dependent.[22][23]

The choice between decompression, early implant and later implant is individualized. PSD outcome estimates come from small retrospective cohorts; the surgeon-preference survey provides no comparative recovery data or individual prognosis.[18][19][20][21]

See Also​

Podcasts​

Managing Ischemic Priapism: Surgical Approaches & Outcomes
BackTable Urology, Ep. 265 (2025) · Maia VanDyke, Juan Andino
backtable.com

Videos​

Priapism — technique demonstration
Ischemic priapism management
Priapism management — operative video
Surgical approach and shunt technique

External video references:

  • Penoscrotal decompression of refractory ischemic priapism — surgical technique. Video Journal of Sexual Medicine (vjsm.info): Residents Corner
  • Penoscrotal decompression — a better method for priapism management. Video Journal of Sexual Medicine (vjsm.info): Full video

References​

1. Pang KH, Alnajjar HM, Lal A, Muneer A. An update on mechanisms and treatment options for priapism. Nat Rev Urol. 2025. doi:10.1038/s41585-025-01069-9

2. Bivalacqua TJ, Allen BK, Brock G, et al. Acute ischemic priapism: an AUA/SMSNA guideline. J Urol. 2021;206(5):1114–1121. doi:10.1097/JU.0000000000002236

3. Bivalacqua TJ, Allen BK, Brock GB, et al. The diagnosis and management of recurrent ischemic priapism, priapism in sickle cell patients, and non-ischemic priapism: an AUA/SMSNA guideline. J Urol. 2022;208(1):43–52. doi:10.1097/JU.0000000000002767

4. Ericson C, Baird B, Broderick GA. Management of priapism: 2021 update. Urol Clin North Am. 2021;48(4):565–576. doi:10.1016/j.ucl.2021.07.003

5. Idris IM, Burnett AL, DeBaun MR. Epidemiology and treatment of priapism in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2022;2022(1):450–458. doi:10.1182/hematology.2022000380

6. Wen J, Jiang X, Dai Y, et al. Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling. FASEB J. 2010;24(3):740–9. doi:10.1096/fj.09-144147

7. Pereira DA, Calmasini FB, Costa FF, Burnett AL, Silva FH. Nitric oxide resistance in priapism associated with sickle cell disease: mechanisms, therapeutic challenges, and future directions. J Pharmacol Exp Ther. 2024;390(2):203–212. doi:10.1124/jpet.123.001962

8. Iacopucci APM, da Silva Pereira P, Pereira DA, et al. Intravascular hemolysis leads to exaggerated corpus cavernosum relaxation: implication for priapism in sickle cell disease. FASEB J. 2022;36(10):e22535. doi:10.1096/fj.202200867R

9. Chinegwundoh FI, Smith S, Anie KA. Treatments for priapism in boys and men with sickle cell disease. Cochrane Database Syst Rev. 2020;4:CD004198. doi:10.1002/14651858.CD004198.pub4

10. Borrell JA, Bettencourt A, Furtado TP, et al. Risk factors, diagnosis, and long-term erectile dysfunction outcomes in priapism: a retrospective analysis of 186 cases from a single institution. Int J Impot Res. 2026;38(1):23–29. doi:10.1038/s41443-025-01076-9

11. von Stempel C, Walkden M, Kirkham A. Review of the role of imaging in the diagnosis of priapism. Int J Impot Res. 2024. doi:10.1038/s41443-024-00928-0

12. McHugh K, Gibbons RC. Point-of-care ultrasound diagnosis of high flow priapism. J Emerg Med. 2022;62(2):207–209. doi:10.1016/j.jemermed.2021.07.037

13. Bobo GA, Almajed W, Conlon J, Morenas RA, Hellstrom WJG. An overview of emergency pharmacotherapy for priapism. Expert Opin Pharmacother. 2022;23(12):1371–1380. doi:10.1080/14656566.2022.2099271

14. Lumbiganon S, Moukhtar Hammad MA, Azad B, Yafi FA. A narrative review of initial treatment for ischemic priapism. Int J Impot Res. 2024. doi:10.1038/s41443-024-00951-1

15. Yassin M, Chen R, Ager M, Desouky E, Minhas S. Penile implants in low flow priapism. Int J Impot Res. 2023;35(7):651–663. doi:10.1038/s41443-023-00787-1

16. El-Bahnasawy MS, Dawood A, Farouk A. Low-flow priapism: risk factors for erectile dysfunction. BJU Int. 2002;89(3):285–90. doi:10.1046/j.1464-4096.2001.01510.x

17. Masterson TA, Parmar M, Tradewell MB, et al. Using artificial intelligence to predict surgical shunts in men with ischemic priapism. J Urol. 2020;204(5):1033–1038. doi:10.1097/JU.0000000000001183

18. Fuchs JS, Shakir N, McKibben MJ, et al. Penoscrotal decompression-promising new treatment paradigm for refractory ischemic priapism. J Sex Med. 2018;15(5):797–802. doi:10.1016/j.jsxm.2018.02.010

19. Baumgarten AS, VanDyke ME, Yi YA, et al. Favourable multi-institutional experience with penoscrotal decompression for prolonged ischaemic priapism. BJU Int. 2020;126(4):441–446. doi:10.1111/bju.15127

20. Basile G, Ralph D, Wardak S, Sangster P, Christopher N, Lee WG. Penoscrotal decompression should be considered for prolonged ischaemic priapism. J Sex Med. 2025;22(11):2072–2078. doi:10.1093/jsxmed/qdaf229

21. VanDyke ME, Smith WJ, Holland LC, et al. Current opinions on the management of prolonged ischemic priapism: does penoscrotal decompression outperform corporoglanular tunneling? Int J Impot Res. 2024;36(1):62–67. doi:10.1038/s41443-023-00808-z

22. Milenkovic U, Cocci A, Veeratterapillay R, et al. Surgical and minimally invasive treatment of ischaemic and non-ischaemic priapism: a systematic review by the EAU Sexual and Reproductive Health Guidelines Panel. Int J Impot Res. 2024;36(1):36–49. doi:10.1038/s41443-022-00604-1

23. Schifano N, Capogrosso P, Baldini S, et al. Current evidence on the management of ischaemic priapism post-shunting: a narrative review. Int J Impot Res. 2025. doi:10.1038/s41443-025-01078-7

24. European Association of Urology. Guidelines on Sexual and Reproductive Health, Limited Update March 2026, section 10 (priapism). Guideline.

25. American Urological Association/Sexual Medicine Society of North America. The Diagnosis and Management of Priapism: an AUA/SMSNA Guideline. 2022. Statements 1–27, Tables 3–5 and Appendices A–B; related journal publications are references 2 and 3. Full guideline.

26. Idris IM, Yusuf AA, Ismail II, et al. A controlled trial for preventing priapism in sickle cell anemia: hydroxyurea plus placebo vs hydroxyurea plus tadalafil. Blood. 2025;145(26). doi:10.1182/blood.2024027898.

27. Levey HR, Segal RL, Bivalacqua TJ. Management of priapism: an update for clinicians. Ther Adv Urol. 2014;6(6):230–244. doi:10.1177/1756287214542096

28. Witt MA, Goldstein I, Saenz de Tejada I, Greenfield A, Krane RJ. Traumatic laceration of intracavernosal arteries: the pathophysiology of nonischemic, high flow, arterial priapism. J Urol. 1990;143(1):129–132. doi:10.1016/s0022-5347(17)39889-0

29. Gordon SA, Bhatt S, Rambhatla A, et al. Conservative management of priapism in acute spinal cord injury. Urology. 2005;65(6):1195–1197. doi:10.1016/j.urology.2004.12.036

30. Wolf JS Jr, Lue TF. High-flow priapism and glans hypervascularization following deep dorsal vein arterialization for vasculogenic impotence. Urol Int. 1992;49(4):227–229. doi:10.1159/000282434

31. Liguori G, Bucci S, Benvenuto S, et al. High-flow priapism (HFP) secondary to Nesbit operation: management by percutaneous embolization and colour Doppler-guided compression. Int J Impot Res. 2005;17(3):304–306. doi:10.1038/sj.ijir.3901251

32. Zargooshi J, Nourizad S, Vaziri S, et al. Nonischemic priapism following penile tattooing. J Sex Med. 2012;9(3):844–848. doi:10.1111/j.1743-6109.2011.02579.x

33. Roghmann F, Becker A, Sammon JD, et al. Incidence of priapism in emergency departments in the United States. J Urol. 2013;190(4):1275–1280. doi:10.1016/j.juro.2013.03.118

34. Stein DM, Flum AS, Cashy J, Zhao LC, McVary KT. Nationwide emergency department visits for priapism in the United States. J Sex Med. 2013;10(10):2418–2422. doi:10.1111/jsm.12251

35. von Stempel C, Zacharakis E, Allen C, et al. Mean velocity and peak systolic velocity can help determine ischaemic and non-ischaemic priapism. Clin Radiol. 2017;72(7):611.e9–611.e16. doi:10.1016/j.crad.2017.02.021

36. Lue TF, Hellstrom WJ, McAninch JW, Tanagho EA. Priapism: a refined approach to diagnosis and treatment. J Urol. 1986;136(1):104–108. doi:10.1016/s0022-5347(17)44746-x

37. Kim KR, Shin JH, Song HY, et al. Treatment of high-flow priapism with superselective transcatheter embolization in 27 patients: a multicenter study. J Vasc Interv Radiol. 2007;18(10):1222–1226. doi:10.1016/j.jvir.2007.06.030

38. Savoca G, Pietropaolo F, Scieri F, et al. Sexual function after highly selective embolization of cavernous artery in patients with high flow priapism: long-term followup. J Urol. 2004;172(2):644–647. doi:10.1097/01.ju.0000132494.44596.33

39. Baba Y, Hayashi S, Ueno K, Nakajo M. Superselective arterial embolization for patients with high-flow priapism: results of follow-up for five or more years. Acta Radiol. 2007;48(3):351–354. doi:10.1080/02841850701199934

40. O'Sullivan P, Browne R, McEniff N, Lee MJ. Treatment of "high-flow" priapism with superselective transcatheter embolization: a useful alternative to surgery. Cardiovasc Intervent Radiol. 2006;29(2):198–201. doi:10.1007/s00270-005-0089-x

41. Sandock DS, Seftel AD, Herbener TE, Goldstein I, Greenfield AJ. Perineal abscess after embolization for high-flow priapism. Urology. 1996;48(2):308–311. doi:10.1016/S0090-4295(96)00176-8

42. Mulhall JP, Jenkins LC. Office Management of Prolonged Erection/Priapism. In: Mulhall JP, Jenkins LC, eds. Atlas of Office Based Andrology Procedures. Springer; 2017:129–133. doi:10.1007/978-3-319-42178-0_18

43. Ralph DJ, Borley NC, Allen C, et al. "The use of high-resolution magnetic resonance imaging in the management of patients presenting with priapism." BJU Int. 2010;106(11):1714–1718. doi:10.1111/j.1464-410X.2010.09368.x